ViroPharma fell the most in three years after generic rivals of its biggest product, the antibiotic Vancocin, received U.S. regulatory approval. ViroPharma declined 22 percent to $22.44 on the Nasdaq, ...

Add Yahoo as a preferred source to see more of our stories on Google. In this series, we use accounts receivable and days sales outstanding to judge a company's current health and future prospects. It ...

ViroPharma Inc. said it expects worldwide products sales of between $450 million and $475 million next year, with North American sales of Cinryze accounting for $390 million to $400 million of that ...

Moreover, the FDA said that Vancocin’s label update in December 2011 would not result in three additional years of the drug’s marketing exclusivity. For an old antibiotic like Vancocin to be eligible ...

The Federal Trade Commision on Tuesday filed a complaint against Shire ViroPharma, claiming the drugmaker abused government processes to prevent generic competition of its antibiotic Vancocin HCl from ...

The US Federal Trade Commission (FTC) on Tuesday filed a complaint against Shire ViroPharma for blocking and delaying the marketing of generic versions of its antibiotic Vancocin (vancomycin), which ...

EXTON, Pa. (AP) — ViroPharma Inc. reported a second-quarter loss as generic competition for the antibiotic Vancocin hurt the drugmaker’s revenue, which tumbled 26 percent. The Exton, Pa., company said ...

EXTON, Pa. (AP) — ViroPharma Inc. said Wednesday that it lost $4 million in the fourth quarter as revenue fell as generic competition eroded sales of its antibiotic Vancocin and its costs increased.

Co says FDA seeks more information Co says to go ahead with manufacturing at risk Says approved process to yield 60,000 doses annually Shares fall as much as 17 pct before the bell Oct 22 (Reuters) - ...

(AP) Drug maker Shire says it is buying the rare disease biopharmaceutical company ViroPharma in a deal worth $4.2 billion. Shire PLC will pay $50 a share, a 27 percent premium on last week’s closing ...

ViroPharma Incorporated VPHM today announced the license of worldwide rights from Intellect Neurosciences, Inc. ILNS to its clinical stage drug candidate, OX1, being developed for the treatment of ...